Amicus Therapeutics (FOLD) Tops Q3 EPS by 1c; Affirms FY16 Net Cash Spend Outlook

November 7, 2016 7:45 AM EST
Get Alerts FOLD Hot Sheet
Price: $6.00 -1.64%

Financial Fact:
Interest expense: -1.52M

Today's EPS Names:
VRNT, OLLI, HRB, More
Trade FOLD Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Amicus Therapeutics (NASDAQ: FOLD) reported Q3 EPS of ($0.33), $0.01 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $2.1 million versus the consensus estimate of $1.71 million.

2016 Financial Guidance

Cash, cash equivalents, and marketable securities totaled $212.4 million at September 30, 2016. As previously announced, the Company strengthened the balance sheet during the third quarter of 2016 with $39.3 million in net proceeds through the at-the-market (ATM) facility and has raised the full $100 million allotted for the ATM facility. The Company expects to remain within the original 2016 net cash spend guidance of between $135 million and $155 million.

For earnings history and earnings-related data on Amicus Therapeutics (FOLD) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Earnings, Guidance

Related Entities

Earnings

Add Your Comment